ModeX to Reveal MDX3001 In Vivo CAR-T Generation and Deep B-Cell Depletion Data
OPKO Health's ModeX will present preclinical data showing its MDX3001 LNP/mRNA candidate generates CAR-T cells in vivo and achieves deep B-cell depletion in blood, spleen, bone marrow and lymph nodes in humanized mouse and non-human primate models. The CD3xCD28 antibody-conjugated LNP platform obviates ex vivo manufacturing and chemotherapy preconditioning.
1. Preclinical Efficacy Data
ModeX’s MDX3001 candidate generated functional CAR-T cells in vivo, resulting in deep systemic B-cell depletion across blood, spleen, bone marrow and lymph nodes in both humanized mouse and non-human primate models. Activity was confirmed in lymphoid tissues, highlighting robust target engagement.
2. Platform Technology
The CD3xCD28 antibody-conjugated LNP/mRNA platform enables direct T-cell transfection, activation and CAR-T generation without ex vivo manufacturing or chemotherapy preconditioning. Its mRNA backbone supports repeat dosing and the expansion of persistent memory T-cell populations.
3. ASGCT Presentation Details
Data will be presented May 14 at the ASGCT 2026 Annual Meeting in Boston under abstract #338, detailing bispecific CD3xCD28 LNP-driven in vivo CAR-T cell generation and B-cell depletion results.